APA (7th ed.) Citation

J, F., B, B., B, D., P, G., & X, R. (2025). Cost-utility of tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in France: A multi-state Markov model analysis. Clinical and experimental rheumatology, 43(1), 62. https://doi.org/10.55563/clinexprheumatol/3f60yv

Chicago Style (17th ed.) Citation

J, Fournier, Boussat B, Dervaux B, Gaudin P, and Romand X. "Cost-utility of Tofacitinib in the Treatment of Moderate-to-severe Rheumatoid Arthritis in France: A Multi-state Markov Model Analysis." Clinical and Experimental Rheumatology 43, no. 1 (2025): 62. https://doi.org/10.55563/clinexprheumatol/3f60yv.

MLA (9th ed.) Citation

J, Fournier, et al. "Cost-utility of Tofacitinib in the Treatment of Moderate-to-severe Rheumatoid Arthritis in France: A Multi-state Markov Model Analysis." Clinical and Experimental Rheumatology, vol. 43, no. 1, 2025, p. 62, https://doi.org/10.55563/clinexprheumatol/3f60yv.